Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

McMaster University

$150,000.00

In vivo clonal evolution of medulloblastoma brain tumour-initiating cells in response to therapy: Discovering the refractory brain tumour-initiating cell population

FY 2011-12

Summary
The Cancer Stem Cell (CSC) hypothesis suggests that tumours are organized into a hierarchy with a rare population of cells, termed CSCs, having the ability to initiate, proliferate, and maintain tumour growth. This is in sharp contrast to all other cells of the bulk tumour, characterized by a limited proliferative capacity and specified lineage potential. Brain tumours represent the leading cause of childhood cancer mortality, of which medulloblastoma is the most frequent malignant pediatric brain tumour. The recent identification of brain cancer stem cells, termed brain tumour-initiating cells (BTICs) has confirmed a stem cell origin for medulloblastoma pathogenesis. The most clinically compelling component of the CSC hypothesis holds that the CSC evades current therapy and is responsible for disease recurrence and metastasis post-therapy. Although there is strong evidence that CSCs are chemo- and radio-resistant, no studies prospectively demonstrate these treatment-resistant CSCs to be exclusively causative in cancer relapse and recurrence. The objective of this study is to generate a global profile of medulloblastoma BTICs as they evolve in response to therapy through gene expression and stem cell biology analyses conducted on our medulloblastoma BTIC mouse model. We hypothesize that comparative BTIC analyses of mice surviving all treatments to those mice that fail therapy will generate a differential profile of the refractory BTIC, and thereby permit the identification of BTICs that respond to or evade specific interventions. For the first time, we will be able to offer a comprehensive molecular profile of the treatment-resistant BTIC population that is responsible for cancer relapse or progression. Novel therapies directed at these specific medulloblastoma stem cells may improve the overall survivorship of medulloblastoma patients, especially in those who remain refractory to current treatment.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
247898
Name
Manoranjan Branavan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
In vivo clonal evolution of medulloblastoma brain tumour-initiating cells in response to therapy: Discovering the refractory brain tumour-initiating cell population
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Brain Tumour Initiating Cells; Cancer Stem Cells; Chemotherapy; Ct-Pet Imaging; Fluorescent-Activated Cell Sorting; Human-Mouse Xenograft Model; Lentiviruses; Medulloblastoma; Microarray Gene Expression Profiling; Radiotherapy
Abstract
The Cancer Stem Cell (CSC) hypothesis suggests that tumours are organized into a hierarchy with a rare population of cells, termed CSCs, having the ability to initiate, proliferate, and maintain tumour growth. This is in sharp contrast to all other cells of the bulk tumour, characterized by a limited proliferative capacity and specified lineage potential. Brain tumours represent the leading cause of childhood cancer mortality, of which medulloblastoma is the most frequent malignant pediatric brain tumour. The recent identification of brain cancer stem cells, termed brain tumour-initiating cells (BTICs) has confirmed a stem cell origin for medulloblastoma pathogenesis. The most clinically compelling component of the CSC hypothesis holds that the CSC evades current therapy and is responsible for disease recurrence and metastasis post-therapy. Although there is strong evidence that CSCs are chemo- and radio-resistant, no studies prospectively demonstrate these treatment-resistant CSCs to be exclusively causative in cancer relapse and recurrence. The objective of this study is to generate a global profile of medulloblastoma BTICs as they evolve in response to therapy through gene expression and stem cell biology analyses conducted on our medulloblastoma BTIC mouse model. We hypothesize that comparative BTIC analyses of mice surviving all treatments to those mice that fail therapy will generate a differential profile of the refractory BTIC, and thereby permit the identification of BTICs that respond to or evade specific interventions. For the first time, we will be able to offer a comprehensive molecular profile of the treatment-resistant BTIC population that is responsible for cancer relapse or progression. Novel therapies directed at these specific medulloblastoma stem cells may improve the overall survivorship of medulloblastoma patients, especially in those who remain refractory to current treatment.
Competitiondate
201111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Manoranjan, Branavan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
McMaster University - $150,000 Grant (2011-12) | Canada Spends